arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Vir Biotechnology, Inc.

VIR
$11.10 ▼ -0.39 (-3.39%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
36 Visible periods
27 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Vir Biotechnology, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $1.9B
Dividend Yield
Revenue Growth 19582.5%
Op. Margin 30.7%
ROIC 7.5%
FCF / Share $0.74
Trailing P/E 23.1x
Price / Book 1.9x
FCF Yield 6.6%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$238.95M
↑ +19582.5%
Net Income Profit after all expenses
$80.08M
↑ +163.7%
Operating Margin Operating profit as % of sales
30.7%
↑ +141.1%
FCF / Share Free cash flow per share
$0.74
↑ +181.6%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.91x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 36 quarters